<DOC>
	<DOCNO>NCT01824290</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy tadalafil pediatric participant pulmonary arterial hypertension . Participants receive study treatment 6 month double-blind period ( Period 1 ) , eligible enroll open-label 2 year extension period ( Period 2 ) participant receive tadalafil .</brief_summary>
	<brief_title>A Study Tadalafil Pediatric Participants With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>≥6 month &lt; 18 year age screen Currently diagnosis PAH either : idiopathic , include hereditary related connective tissue disease relate anorexigen use associate surgical repair least 6month duration congenital systemic pulmonary shunt ( eg , atrial septal defect , ventricular septal defect , patent ductus arteriosus ) Have history diagnosis PAH establish rest mean pulmonary artery pressure ( mPAP ) ≥25 millimeter mercury ( mm Hg ) , pulmonary artery wedge pressure ≤15 mm Hg , pulmonary vascular resistance ( PVR ) ≥3 Wood unit via right heart catheterization ( RHC ) . In event pulmonary artery wedge pressure obtain RHC , participant leave ventricular end diastolic pressure ( LVEDP ) &lt; 15 mm Hg , normal leave heart function , absence mitral stenosis echocardiography eligible enrollment Have World Health Organization ( WHO ) functional class value II III time screen All participant must receive endothelin receptor antagonist ( ERA ) ( bosentan ambrisentan ) must maintenance dose change dose ( weightbased adjustment ) least 12 week prior screen screen aspartate transaminase ( AST ) /alanine transaminase ( ALT ) &lt; 3 time upper limit normal ( ULN ) If conventional PAH medication , include restrict , anticoagulant , diuretic , digoxin , oxygen therapy , participant must stable dos change ( weightbased adjustment ) least 4 week screen Female participant childbearing potential must test negative pregnancy screen . Furthermore , female participant must agree abstain sexual activity use two different reliable method birth control determine Investigator study . Examples reliable birth control method include true abstinence lifestyle choice ( periodic sexual abstinence method acceptable ) ; use oral contraceptive ; reliable barrier method birth control ( diaphragms contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ; intrauterine device ) Written informed consent parent ( write assent appropriately age participant ) obtain prior study procedure perform Have pulmonary hypertension relate condition specify , include limited chronic thromboembolic disease , portal pulmonary hypertension , leftsided heart disease lung disease hypoxia History leftsided heart disease , include follow : clinically significant [ pulmonary artery occlusion pressure ( PAOP ) 1518 mm Hg ] aortic mitral valve disease ( ie , aortic stenosis , aortic insufficiency , mitral stenosis , moderate great mitral regurgitation ) pericardial constriction restrictive congestive cardiomyopathy leave ventricular ejection fraction &lt; 40 % multigated radionucleotide angiogram ( MUGA ) , angiography , echocardiography leave ventricular shorten fraction &lt; 22 % echocardiography lifethreatening cardiac arrhythmia symptomatic coronary artery disease within 5 year study entry Unrepaired congenital heart disease Have history angina pectoris condition treat long shortacting nitrate within 12 week administration study drug Have severe hepatic impairment , ChildPugh Grade C Have severe renal insufficiency , define receive renal dialysis measure estimate creatinine clearance ( CC ) &lt; 30 millimeter per minute ( mL/min ) ( Schwartz Formula ) Diagnosed retinal disorder ( eg , hereditary retinal disorder , retinopathy preterm participant retinal disorder ) Have severe hypotension uncontrolled hypertension determine Investigator Have significant parenchymal lung disease Have bronchopulmonary dysplasia Concurrent phosphodiesterase type 5 ( PDE5 ) inhibitor therapy ( sildenafil vardenafil ) receive PDE5 inhibitor therapy within 12 week prior first study drug dose Concurrent therapy prostacyclin analogue within 12 week screen Commenced discontinue chronic conventional PAH medication include restrict : diuretic , anticoagulant , digoxin , oxygen therapy within 4 week screen Currently receive treatment doxazosin , nitrate , cancer therapy Current treatment potent Cytochrome P450 3A4 ( CYP3A4 ) inhibitor , antiretroviral therapy ( protease inhibitor ) , systemic ketoconazole , systemic itraconazole , chronic use potent CYP3A4 inducer , rifampicin Are nurse pregnant Have previously complete withdrawn study ( LVHV ) , study investigate tadalafil Have receive tadalafil therapy within 12 week prior first study drug dose hypersensitive tadalafil Have allergy excipients , notably lactose Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Sponsor Unable take orally administer tablet ( without chewing , crush break ) suspension Are Investigator site personnel directly affiliate study immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt Diagnosis Down syndrome</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>